Skip to main content
Sirio Pharma Co., Ltd. logo

Sirio Pharma Co., Ltd. - Investor Relations & Filings

Listed IPO Sep 2019
Ticker · 300791 ISIN · CNE100003NB0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,184 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300791 · 1 venue

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
2026-072 关于关停个人护理业务的公告
Regulatory Filings Classification · 70% confidence The document is a corporate announcement about the company’s decision to shut down its personal care business following a board meeting resolution. It is not an earnings release, management change, M&A deal, or financial report, but rather a standard regulatory disclosure of an operational decision. It falls into the miscellaneous category of regulatory filings rather than a specific report type.
2026-04-23 Chinese
招商证券股份有限公司关于仙乐健康科技股份有限公司2025年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 90% confidence The document is a detailed “专项核查意见” (special verification opinion) on the storage, management, and use of funds raised by 仙乐健康科技股份有限公司 for 2025, including tables of fund balances, usage, and auditor (德勤华永会计师事务所) review opinions as well as sponsor (招商证券) opinions. It is not an Annual Report or earnings release but a standalone audit/verification report on the raised funds as required by regulators. This matches the “Audit Report / Information (AR)” category. FY 2025
2026-04-23 Chinese
关于会计师事务所履职情况的评估报告
Audit Report / Information Classification · 85% confidence The document is titled “关于会计师事务履职情况的评估报告” and provides a detailed evaluation of the external auditor (Deloitte Huayong) performance, independence, and audit process for the 2025 fiscal year, including regulatory references, auditor credentials, scope of audit, and the board’s assessment. It is not the full annual report nor a brief announcement but a standalone audit‐related report required by corporate and securities laws. Therefore it falls under Audit Report / Information (AR). FY 2025
2026-04-23 Chinese
关于增加公司对子公司申请银行授信预计提供担保进展的公告
Capital/Financing Update Classification · 75% confidence The document is a regulatory announcement by a listed company detailing the progress of providing joint‐and‐several guarantees for its subsidiary’s bank credit facilities (increasing guarantee amounts and summarizing terms). It is not a financial report, board change, dividend notice, or share issue, but rather an update on financing activities (the company’s provision of guarantees for debt). This aligns with the “Capital/Financing Update” category (CAP).
2026-04-15 Chinese
关于可转换公司债券2026年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment on a convertible bond issued by the company. It details the bond terms, interest rates, payment dates, tax information, and procedural details for the bond interest payment scheduled for 2026. It does not contain financial statements, management discussion, or detailed financial results. The document is relatively short (4500 characters) and serves as a formal notice about the bond interest payment rather than a full financial report or audit. This fits the category of a Capital/Financing Update (CAP) as it relates to bond financing and interest payment information.
2026-04-13 Chinese
关于仙乐转债回售结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of a convertible bond repurchase (回售结果的公告). It provides details such as bond code, repurchase price, repurchase period, and the outcome (no bonds were repurchased). It also states the impact on the company and subsequent matters. The document is short (1163 characters) and is a formal announcement of a specific financing event outcome, not a full financial report or detailed analysis. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2026-04-07 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.